Teleflex
Market Cap
US$17.0b
Last Updated
2019/08/20 23:48 UTC
Data Sources
Company Financials +
Executive Summary
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide.
Snowflake
Fundamentals
Moderate growth potential with questionable track record.
Similar Companies
Share Price & News
How has Teleflex's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-0.7%
NYSE:TFX
-0.08%
US Medical Equipment
0.2%
US Market
1 Year Return
51.0%
NYSE:TFX
14.1%
US Medical Equipment
-0.7%
US Market
TFX outperformed the Medical Equipment industry which returned 14.7% over the past year.
TFX outperformed the Market in United States of America which returned 0.3% over the past year.
Share holder returns
| TFX | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.7% | -0.08% | 0.2% |
| 30 Day | 9.8% | 0.5% | -2.7% |
| 90 Day | 23.5% | 10.2% | 1.6% |
| 1 Year | 51.7%51.0% | 15.0%14.1% | 1.6%-0.7% |
| 3 Year | 105.5%102.0% | 68.4%63.2% | 40.0%30.9% |
| 5 Year | 249.9%237.1% | 131.5%104.9% | 53.8%36.8% |
Price Volatility Vs. Market
How volatile is Teleflex's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
Have Insiders Sold Teleflex Incorporated (NYSE:TFX) Shares Recently?2 weeks ago | Simply Wall St
Don't Sell Teleflex Incorporated (NYSE:TFX) Before You Read This4 weeks ago | Simply Wall St
The Teleflex (NYSE:TFX) Share Price Has Gained 214%, So Why Not Pay It Some Attention?Valuation
Is Teleflex undervalued based on future cash flows and its price relative to the stock market?
62.86x
Price to Earnings (PE) ratio
Intrinsic Value Based on Future Cash Flows
Teleflex's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
Teleflex's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Price Based on Earnings
Teleflex is overvalued based on earnings compared to the US Medical Equipment industry average.
Teleflex is overvalued based on earnings compared to the United States of America market.
Price Based on Expected Growth
Teleflex is poor value based on expected growth next year.
Price Based on Value of Assets
Teleflex is overvalued based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is Teleflex expected to perform in the next 1 to 3 years based on estimates from 13 analysts?
29.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Teleflex's revenue is expected to grow by 7.3% yearly, however this is not considered high growth (20% yearly).
Teleflex's earnings are expected to grow significantly at over 20% yearly.
Teleflex's revenue growth is positive but not above the United States of America market average.
Teleflex's earnings growth is expected to exceed the United States of America market average.
Teleflex's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Teleflex is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Next Steps
Past Performance
How has Teleflex performed over the past 5 years?
-2.1%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Teleflex's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
Teleflex's 1-year earnings growth exceeds its 5-year average (199.8% vs -2.1%)
Teleflex's earnings growth has exceeded the US Medical Equipment industry average in the past year (199.8% vs 28.9%).
Return on Equity
Teleflex has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
Return on Assets
Teleflex used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.
Return on Capital Employed
Teleflex's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is Teleflex's financial position?
Financial Position Analysis
Teleflex is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Teleflex's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
Teleflex's level of debt (80.2%) compared to net worth is high (greater than 40%).
The level of debt compared to net worth has increased over the past 5 years (53.5% vs 80.2% today).
Debt is not well covered by operating cash flow (19.5%, less than 20% of total debt).
Interest payments on debt are well covered by earnings (EBIT is 5.4x coverage).
Balance Sheet
Low level of unsold assets.
Debt is not covered by short term assets, assets are 0.6x debt.
Next Steps
Dividend
What is Teleflex's current dividend yield, its reliability and sustainability?
0.37%
Expected Dividend Yield
Dividend Yield and Payments Analysis
Teleflex's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.48%).
Teleflex's dividend is below the markets top 25% of dividend payers in United States of America (3.83%).
Teleflex is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.
Teleflex is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.
Current Payout to Shareholders
No need to calculate the sustainability of Teleflex's dividends as it is not paying a notable one for United States of America.
Future Payout to Shareholders
No need to calculate the sustainability of Teleflex's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of Teleflex's salary, the management and board of directors tenure and is there insider trading?
5.8yrs
Average management tenure
CEO
Liam Kelly (52yo)
1.6yrs
Tenure
US$6,108,486
Compensation
Mr. Liam J. Kelly has been Chief Executive Officer at Teleflex Incorporated since January 01, 2018 and has been its Director since May 4, 2018. Mr. Kelly has been the President at Teleflex Incorporated sin ...
CEO Compensation Analysis
Liam's remuneration is lower than average for companies of similar size in United States of America.
Liam's compensation has been consistent with company performance over the past year, both up more than 20%.
Management Age and Tenure
5.8yrs
Average Tenure
52yo
Average Age
The average tenure for the Teleflex management team is over 5 years, this suggests they are a seasoned and experienced team.
Board Age and Tenure
2.9yrs
Average Tenure
64yo
Average Age
The average tenure for the Teleflex board of directors is less than 3 years, this suggests a new board.
Insider Trading
Teleflex individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Accounting Officer VP & Chief Accounting Officer |
| Shares | 403 |
| Max Price | US$365.53 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 3,000 |
| Max Price | US$330.39 |
| Entity | Individual |
| Role | Chief Accounting Officer VP & Chief Accounting Officer |
| Shares | 384 |
| Max Price | US$287.18 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 1,250 |
| Max Price | US$285.00 |
| Entity | Individual |
| Shares | 829 |
| Max Price | US$268.91 |
Ownership Breakdown
Management Team
Tom Powell (57yo)
Executive VP & CFO
- Tenure: 7.4yrs
- Compensation: US$2.89m
Gwen Watanabe (47yo)
Vice President of Global Corporate Development & Strategy
- Tenure: 6.1yrs
James Leyden (52yo)
VP, General Counsel & Secretary
- Tenure: 5.5yrs
- Compensation: US$1.45m
Dave Amerson
President & GM of Interventional Urology
- Tenure: 0.0yrs
Jake Elguicze (46yo)
VP of Investor Relations & Treasurer
- Tenure: 0.0yrs
Liam Kelly (52yo)
President
- Tenure: 1.6yrs
- Compensation: US$6.11m
Gwen Chapman (44yo)
Chief Compliance Officer & VP
- Tenure: 0.0yrs
Cam Hicks (54yo)
VP of Global Human Resources & Employee Communications
- Tenure: 6.3yrs
- Compensation: US$1.13m
John Deren
VP & Chief Accounting Officer
- Tenure: 2.3yrs
Tim Duffy
Chief Information Officer & VP
- Tenure: 0.0yrs
Board Members
George Babich (67yo)
Lead Director
- Tenure: 0.0yrs
- Compensation: US$278.45k
John Heinmiller (64yo)
Director
- Tenure: 0.6yrs
Gretchen Frances Haggerty (63yo)
Director
- Tenure: 2.9yrs
- Compensation: US$239.40k
Richard Packer (61yo)
Director
- Tenure: 2.3yrs
- Compensation: US$239.40k
Benson Smith (71yo)
Chairman of the Board
- Tenure: 8.6yrs
- Compensation: US$318.31k
Stu Randle (59yo)
Director
- Tenure: 10.3yrs
- Compensation: US$259.40k
Andy Krakauer (64yo)
Director
- Tenure: 1.6yrs
- Compensation: US$372.08k
Stephen Klasko (65yo)
Independent Director
- Tenure: 11.3yrs
- Compensation: US$236.40k
Candace Duncan (66yo)
Director
- Tenure: 4.3yrs
- Compensation: US$246.06k
Liam Kelly (52yo)
President
- Tenure: 1.6yrs
- Compensation: US$6.11m
Company Information
Teleflex Incorporated's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Teleflex Incorporated
- Ticker: TFX
- Exchange: NYSE
- Founded: 1943
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$17.007b
- Shares outstanding: 46.23m
- Website: https://www.teleflex.com
Number of Employees
Location
- Teleflex Incorporated
- 550 East Swedesford Road
- Suite 400
- Wayne
- Pennsylvania
- 19087
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TFX | NYSE (New York Stock Exchange) | Yes | Common Shares | US | USD | Jan 1968 |
| TBH | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jan 1968 |
Biography
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offe ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/08/20 23:48 |
| End of Day Share Price | 2019/08/20 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.